Blog Category

Press Releases

Biophytis – Convening of Another Combined General Meeting at a Later Date

,

/

27 April 2021

Biophytis gives operational perspectives on its Sarconeos (BIO101) ahead of its upcoming AGM on April 26, 2021 Read the presse release

,

/

26 April 2021

Biophytis Identifies False Report Regarding COVA Study

,

/

14 April 2021

Biophytis gives updates on its Phase 2-3 COVA study on COVID-19

,

/

22 March 2021

Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd

,

/

22 March 2021

Biophytis AGM meeting will take place on April 26, 2021

,

/

11 March 2021

Biophytis Reports 2020 Full Year Results

,

/

26 February 2021

Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) following Regulatory Authorities approvals in France and Belgium

,

/

17 February 2021

Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market

,

/

15 February 2021

Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market

,

/

10 February 2021

Biophytis Announces Temporary Trading Halt of its Shares and Share Warrants on Euronext Growth

,

/

10 February 2021

Biophytis Announces Trading Resumption of its Ordinary Shares and Share Warrants on Euronext

,

/

10 February 2021